Head-to-head evidence
Capmatinib vs Savolitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline
Capmatinib
Marketed by Novartis and partners
NCT04427072 · Phase 3 · terminated
This randomized, open-label trial compared capmatinib to docetaxel in patients with MET exon 14-mutant lung cancer, but enrolled only 22 participants (15 on capmatinib, 7 on docetaxel) before the sponsor terminated the study early. Median progression-free survival was numerically longer with capmatinib (6.1 vs 4.1 months), but the confidence intervals were wide and overlapping and no formal statistical test was reported, so this severely underpowered trial cannot reliably show whether capmatinib truly outperformed docetaxel.
Next expected readout: October 2026 · NCT03333343 (registry estimate)
Savolitinib · Orpathys
Marketed by AstraZeneca and partners
NCT05015608 · Phase 3 · completed
The trial randomized 216 participants to savolitinib plus osimertinib or active chemotherapy, but treatment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT04322890 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Capmatinib's landscape · Savolitinib's landscape